Abstract

The relationship of SARS-CoV-2 pulmonary infection and severity of disease is not fully understood. Here we show analysis of autopsy specimens from 24 patients who succumbed to SARS-CoV-2 infection using a combination of different RNA and protein analytical platforms to characterize inter-patient and intra-patient heterogeneity of pulmonary virus infection. There is a spectrum of high and low virus cases associated with duration of disease. High viral cases have high activation of interferon pathway genes and a predominant M1-like macrophage infiltrate. Low viral cases are more heterogeneous likely reflecting inherent patient differences in the evolution of host response, but there is consistent indication of pulmonary epithelial cell recovery based on napsin A immunohistochemistry and RNA expression of surfactant and mucin genes. Using a digital spatial profiling platform, we find the virus corresponds to distinct spatial expression of interferon response genes demonstrating the intra-pulmonary heterogeneity of SARS-CoV-2 infection.

Understanding the pathology in the lungs of patients with COVID-19 might provide clues as to the susceptibility of patients and how the SARS-CoV-2 virus can be fatal. Here the authors analyze cadaveric pulmonary tissue and show one group with high viral load, early death, inflammation and inflammatory damage, and another with low viral load, longer duration of disease, and more M2-like polarization and fibrotic lung damage.

Details

Title
Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection
Author
Desai Niyati 1 ; Azfar, Neyaz 1 ; Szabolcs Annamaria 1   VIAFID ORCID Logo  ; Shih, Angela R 2 ; Chen, Jonathan H 3 ; Thapar Vishal 1 ; Nieman, Linda T 1 ; Solovyov Alexander 4 ; Mehta Arnav 5 ; Lieb, David J 6 ; Kulkarni, Anupriya S 1 ; Jaicks Christopher 1 ; Xu, Katherine H 1 ; Raabe, Michael J 1 ; Pinto, Christopher J 1 ; Juric Dejan 1   VIAFID ORCID Logo  ; Chebib Ivan 2 ; Colvin, Robert B 2   VIAFID ORCID Logo  ; Kim, Arthur Y 7 ; Monroe, Robert 8 ; Warren, Sarah E 9 ; Danaher, Patrick 9   VIAFID ORCID Logo  ; Reeves, Jason W 9 ; Gong Jingjing 9 ; Rueckert Erroll H 9 ; Greenbaum, Benjamin D 4 ; Hacohen Nir 10   VIAFID ORCID Logo  ; Lagana, Stephen M 11 ; Rivera, Miguel N 12 ; Sholl, Lynette M 13   VIAFID ORCID Logo  ; Stone, James R 2   VIAFID ORCID Logo  ; Ting, David T 14   VIAFID ORCID Logo  ; Deshpande Vikram 3   VIAFID ORCID Logo 

 Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924) 
 Massachusetts General Hospital, Department of Pathology, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924) 
 Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts General Hospital, Department of Pathology, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924) 
 Memorial Sloan Kettering Cancer Center, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952) 
 Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); The Broad Institute, Cambridge, USA (GRID:grid.66859.34) 
 The Broad Institute, Cambridge, USA (GRID:grid.66859.34) 
 Massachusetts General Hospital, Department of Medicine, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924) 
 Advanced Cell Diagnostics, a Bio-Techne Brand, Newark, USA (GRID:grid.417415.2) 
 NanoString Inc., Seattle, USA (GRID:grid.417415.2) 
10  Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); The Broad Institute, Cambridge, USA (GRID:grid.66859.34); Massachusetts General Hospital, Department of Medicine, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924) 
11  Columbia University Irving Medical Center, Department of Pathology and Cell Biology, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729) 
12  Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts General Hospital, Department of Pathology, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); The Broad Institute, Cambridge, USA (GRID:grid.66859.34) 
13  Brigham and Woman’s Hospital, Department of Pathology, Boston, USA (GRID:grid.66859.34) 
14  Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts General Hospital, Department of Medicine, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2473295279
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.